QUAL A MELHOR OPÇÃO ENTRE OS BIOLÓGICOS E INIBIDORES DA JAK PARA O TRATAMENTO DA ARTRITE RELACIONADA À ENTESITE EM MENORES DE 18 ANOS: UMA META-ANÁLISE

Doi: 10.47094/CESMED.2025/60

PALAVRAS CHAVE: Biológicos. Crianças. Entesite. Inibidores de JAK. Placebo.

KEYWORDS: Biologics. Children. Enthesitis. JAK inhibitors. Placebo.

ABSTRACT:
INTRODUCTION: Enthesitis-associated arthritis (ERA) is an autoimmune condition associated with the genetic factor HLA-B27 that affects the joints and entheses of the lower extremities in children. Compared to other types of juvenile idiopathic arthritis, ERA has a higher likelihood of recurrence after initial treatment. Therefore, it is a problem associated with children and adolescents, in whom medications are used for the symptoms and inflammation caused by ERA. OBJECTIVE: To determine the best intervention between biologics and Janus kinase (JAK) inhibitors for the treatment of ERA.

Autores

• Gabriel Alves Barbosa

• Itamar Fernandes Souza Júnior

• Otaviano Ottoni da Silva Netto

• Sofia Elisa de Araújo Lira